Adaptin Bio, Inc. Files 8-K with Board and Compensation Updates
Ticker: APTN · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1938571
| Field | Detail |
|---|---|
| Company | Adaptin Bio, Inc. (APTN) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $240,000, $300,000, $75,000, $150,000, b, $10,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing-update
Related Tickers: ADPT
TL;DR
Adaptin Bio (ADPT) filed an 8-K detailing board changes and executive pay. Watch for updates.
AI Summary
Adaptin Bio, Inc. announced on October 3, 2025, changes related to its board of directors and executive compensation. The filing also includes other events and financial statements/exhibits. The company was formerly known as Unite Acquisition 1 Corp. before a name change on July 19, 2022.
Why It Matters
This 8-K filing indicates potential shifts in corporate governance and executive compensation, which could impact the company's strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can signal internal shifts that may affect future performance and strategy.
Key Players & Entities
- Adaptin Bio, Inc. (company) — Registrant
- Unite Acquisition 1 Corp. (company) — Former Company Name
- October 3, 2025 (date) — Date of Earliest Event Reported
- July 19, 2022 (date) — Date of Name Change
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers', but the specific details of these changes are not provided in the provided text.
What are the key updates regarding compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of information, but the specific details of these arrangements are not included in the provided text.
When did Adaptin Bio, Inc. change its name from Unite Acquisition 1 Corp.?
Adaptin Bio, Inc. changed its name from Unite Acquisition 1 Corp. on July 19, 2022.
What is the primary business of Adaptin Bio, Inc.?
Adaptin Bio, Inc. is in the business of Biological Products (No Diagnostic Substances), with a Standard Industrial Classification code of 2836.
What is the filing date and the earliest event date for this 8-K?
This 8-K was filed on October 6, 2025, and the earliest event reported is dated October 3, 2025.
Filing Stats: 918 words · 4 min read · ~3 pages · Grade level 11.3 · Accepted 2025-10-06 16:05:40
Key Financial Figures
- $240,000 — ngly, his current annual base salary of $240,000 per year is increased to an annual rate
- $300,000 — year is increased to an annual rate of $300,000 on a pro-rated basis, beginning July 1,
- $75,000 — ngly, his current annual base salary of $75,000 per year is increased to an annual rate
- $150,000, b — year is increased to an annual rate of $150,000, beginning October 3, 2025. Further, the H
- $10,000,000 — l securities raising aggregate funds of $10,000,000 (in one or more transactions), occurrin
Filing Documents
- ea0260272-8k_adaptin.htm (8-K) — 28KB
- ea026027201ex10-1_adaptin.htm (EX-10.1) — 11KB
- ea026027201ex10-2_adaptin.htm (EX-10.2) — 15KB
- 0001213900-25-096532.txt ( ) — 225KB
- cik0001938571-20251003.xsd (EX-101.SCH) — 3KB
- cik0001938571-20251003_lab.xml (EX-101.LAB) — 33KB
- cik0001938571-20251003_pre.xml (EX-101.PRE) — 22KB
- ea0260272-8k_adaptin_htm.xml (XML) — 4KB
02 DEPARTURE
ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION of DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. On October 3, 2025, Adaptin Bio, Inc. (the "Company") and its Chief Financial Officer, Timothy L. Maness, entered into an amendment to Mr. Maness' Executive Employment Agreement dated February 11, 2025 (the "Maness Employment Amendment"). The Maness Employment Amendment specifies that, as of July 1, 2025, Mr. Maness is employed full-time and devotes substantially all, rather than 80%, of his business time, attention, and efforts as Chief Financial Officer of the Company. Accordingly, his current annual base salary of $240,000 per year is increased to an annual rate of $300,000 on a pro-rated basis, beginning July 1, 2025. The foregoing summary of the Maness Employment Amendment is subject to the full and complete terms of the Maness Employment Amendment, filed as Exhibit 10.1 to this Current Report on Form 8-K. ITEM 8.01 OTHER EVENTS. On October 3, 2025, the Company and its Chief Development Officer, L. Arthur Hewitt, entered into an amendment to Dr. Hewitt's Executive Employment Agreement, dated February 11, 2025 (the "Hewitt Employment Amendment"). The Hewitt Employment Amendment specifies that, as of October 3, 2025, Dr. Hewitt will devote approximately 50%, rather than 25%, of his business time, attention, and efforts as Chief Development Officer of the Company. Accordingly, his current annual base salary of $75,000 per year is increased to an annual rate of $150,000, beginning October 3, 2025. Further, the Hewitt Employment Amendment provides that in the event the Company issues additional securities raising aggregate funds of $10,000,000 (in one or more transactions), occurring, if at all, within two years of February 11, 2025 (the "Additional Financing Period"), the Company, subject to approval by the board of directors and the terms of the Company's equity compensation plan then in place, will grant